Ruxience 100 mg concentrate for solution for infusion

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, Amsterdam UMC, UZ Leuven

Conditions

Follicular LymphomaRelapsed or Refractory Diffuse Large B-Cell LymphomaRheumatoid arthritismultiple sclerosis

Phase 2

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

RecruitingCTIS2022-502646-27-00

Merck Sharp & Dohme LLCRelapsed or Refractory Diffuse Large B-Cell Lymphoma

Start: 2022-06-24Target: 35Updated: 2025-11-17

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

Not yet recruitingCTIS2025-522777-10-00

Merck Sharp & Dohme LLCFollicular Lymphoma

Target: 2Updated: 2026-06-09

Phase 4

Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

Active, not recruitingCTIS2022-502664-21-00

Amsterdam UMCmultiple sclerosis

Start: 2023-05-01Target: 200Updated: 2025-10-14

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthritis: The RITUXERA Trial.

RecruitingCTIS2023-506638-59-01

UZ LeuvenRheumatoid arthritis

Start: 2024-01-09Target: 134Updated: 2025-08-27

Related Papers

Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA).

2024-10-151 citations